Based on the existing varieties, brands, channels and marketing advantages, Jointown conducts targeted development of self-operated industrial and OEM products by virtue of big data accumulated by the Company's "hundred-billion-level" supply chain service platform, and then distributes pharmaceuticals to terminal or C-end consumers through its full-channel sales network.

Beijing Jingfeng Pharmaceutical Group Co., Ltd. (hereinafter "Jingfeng Pharmaceutical"), currently holds more than 200 approval numbers for formulations and active pharmaceutical ingredients (API). Its star product series includes Metformin Hydrochloride Tablets, Glycerol Enema, and Halcinonide Topical Solution, covering therapeutic areas such as systemic anti-infection, digestive system and metabolism, dermatology, neurology, cardio-cerebrovascular system, and respiratory system. To date, 16 drug varieties have passed consistency evaluation. During the reporting period, the Company's Trihexyphenidyl Hydrochloride Tablets passed the generic drug quality and efficacy consistency evaluation. Bupivacaine Hydrochloride Injection obtained a Drug Registration Certificate. Azelastine Hydrochloride received an approval notice for its chemical API market application. Betahistine Hydrochloride Tablets and Azelastine Hydrochloride Nasal Spray were accepted for drug registration. In addition, 7 product specifications, including Rosuvastatin Calcium Tablets, were selected for continued national centralized procurement, while Telmisartan Tablets and Terbinafine Hydrochloride Cream were newly added to the National Essential Medicines List (2026 Edition). In terms of drug research and development, Jingfeng Pharmaceutical focuses on four major series: glucose-lowering, topical, cardio-cerebrovascular, and anti-infection drugs. New products under development include 25 formulations and 11 APIs, and the Company obtained 7 patents, including one for a salicylic acid liniment and its preparation method. In terms of drug production, Jingfeng Pharmaceutical operates more than 30 production lines across 15 dosage forms certified by China's CFDA, along with special formulation lines for topical hormones and anti-tumor drugs, as well as 18 supporting API production lines. During the reporting period, the high-end formulation workshop of a subsidiary under Jingfeng Pharmaceutical passed a drug GMP compliance inspection.

Jiuxin TCM Group Co., Ltd. (hereinafter "Jiuxin TCM"), owns three Chinese herbal pieces brands, namely "Jiuxin", "Jiu Xin Tang", and "Xinyiyuan", as well as the health food brand "Chixiaoyang". Its products span six major series: standard decoction pieces, refined decoction pieces, directly orally administered decoction pieces, toxic decoction pieces, premium tonic herbs such as ginseng and antler, and homology of medicine and food products. The Company offers more than 300 product varieties and over 7,300 product specifications, meeting diverse market demands from medical institutions, retail terminals, and general health and wellness consumers. In addition, Jiuxin TCM has established 13 GMP-certified modern decoction pieces enterprises, including one national CMA laboratory and three CNAS-accredited national laboratories. It has built three national-level and nine provincial-level R&D platforms, undertaken more than 30 national and provincial-ministerial projects, participated in the formulation of 50 national and local standards, mastered more than 20 core techniques for Chinese medicine processing, and holds more than 200 authorized patents. During the reporting period, Jiuxin TCM focused on the research and development of new and specialty decoction pieces, obtaining three invention patents, including one for Honey-Processed Gastrodia elata Slices. Three of its products, namely "Fritillariae Cirrhosae Bulbus Powder", "Angelica sinensis Decoction Pieces", and "Jiuzihe Poria", were selected as provincial benchmark brands under the "Hubei Premium Quality" program.

Jointown Medical Devices Group Co., Ltd., has built an integrated industrial capability covering research and development registration, clinical services, product marketing, and production management. It owns two proprietary brands, "Metiko" and "Flo's", and has obtained 21 MAH Class II product registration certificates, along with 232 OEM device product specifications. During the reporting period, the Company introduced 26 high-quality products, further enhancing its industrial product matrix and driving rapid growth in its device manufacturing and OEM businesses.